Profile: Omeros Corp (OMER.OQ)
21 Aug 2014
Omeros Corporation, incorporated on June 16, 1994, is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. Its product candidates are derived from its PharmacoSurgerytm platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Its PharmacoSurgery platform is based on low-dose combinations of therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to preemptively inhibit inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery. The Company has six ongoing clinical development programs, including four from its PharmacoSurgery platform and two from its addiction franchise.
The Company generates from its PharmacoSurgery platform product candidates that are combinations of therapeutic agents designed to act simultaneously at multiple discrete targets to preemptively block the molecular-signaling and biochemical cascade caused by surgical trauma and to provide clinical benefits both during and after surgery. Its PharmacoSurgery product candidates are added to standard surgical irrigation solutions and delivered intra-operatively to the site of tissue trauma throughout the surgical procedure. OMS103HP is a PharmacoSurgery product candidate being developed for use during arthroscopic procedures, including arthroscopic anterior cruciate ligament (ACL) reconstruction surgery and partial meniscectomy surgery, and was designed to provide a multimodal approach to preemptively block the inflammatory cascade induced by arthroscopy. OMS103HP is a combination of anti-inflammatory/analgesic APIs, with pharmacologic profiles. OMS103HP contains three APIs, which includes Ketoprofen, Amitriptyline and Oxymetazoline.
In its peroxisome proliferator-activated receptor gamma (PPARg) program, the Company develops compositions that include PPARg agonists for the treatment and prevention of addiction to substances of abuse, which may include opioids, nicotine and alcohol. It develops antifibrinolytic agents for the control of blood loss during surgery or resulting from trauma. Phosphodiesterase 10 (PDE10) is an enzyme that is expressed in areas of the brain strongly linked to schizophrenia and other psychotic disorders and has been identified as a target for the development of anti-psychotic therapeutics. The Company develops compounds that inhibit PDE10 for the treatment of schizophrenia and other psychotic disorders.
The Company’s phosphodiesterase 7, (PDE7) program is based on its discoveries of previously unknown links between PDE7 and any addiction or compulsive disorder and between PDE7 and any movement disorders, such as Parkinson’s disease. Mannan-binding lectin-associated serine protease-2 (MASP-2) is a pro-inflammatory protein target involved in activation of the complement system, which is an important component of the immune system. The Company has completed a series of in vivo studies using MASP-2.
201 Elliott Avenue West
SEATTLE WA 98119